Breakthrough Cancer Pain Clinical Trial
Official title:
A Spanish , Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)
National multicenter, prospective, observational study in cancer patients with chronic
background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic
condition by a specialist in the treatment of cancer pain conditions.
• Study objectives include assessment of early treatment satisfaction.
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Recruiting |
NCT01693328 -
Patient Satisfaction and Quality of Life Impact - PecFent®
|
N/A | |
Completed |
NCT01936636 -
Observational Registry Study of Quality of Life When Treating BTcP With Abstral
|
N/A | |
Completed |
NCT05531422 -
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
|
Phase 2 | |
Completed |
NCT03669263 -
A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan
|
N/A | |
Completed |
NCT02899884 -
Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
|
||
Recruiting |
NCT03564548 -
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
|
Phase 2 | |
Not yet recruiting |
NCT04713189 -
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
|
Phase 1/Phase 2 | |
Completed |
NCT03895762 -
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
|
||
Terminated |
NCT01439919 -
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
|
Phase 2 | |
Completed |
NCT01045603 -
Instanyl® Non-Interventional Study
|
N/A | |
Recruiting |
NCT00822614 -
Safety of Fentanyl TAIFUN Treatment
|
Phase 3 | |
Terminated |
NCT04468490 -
Treatment of Breakthrough Cancer Pain According to European Guidelines
|